D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Fp531real-world treatment and clinical outcomes in end-stage renal disease patients with severe hyperkalemia undergoing hemodialysis in the united states
Patent
Bifunctional antifungal agents and methods of treating fungal infection
TL;DR: In this paper, a bifunctional compound which is useful in the treatment of fungal infections is presented, where each compound contains at least one fungal binding moiety (FBM) which is linked to at least two antibody binding moieties (ABT group) through a linker group, which optionally comprises a connector group.
Journal ArticleDOI
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).
Ezra Y. Rosen,Ian M. Silverman,Elisa Fontana,Elizabeth K. Lee,David Spiegel,Martin Højgaard,Stephanie Lheureux,Niharika B. Mettu,Benedito A. Carneiro,Louise Carter,Elizabeth Ruth Plummer,Joseph D. Schonhoft,Danielle B. Ulanet,P. Manley,Jorge S. Reis-Filho,Yi Xu,Victoria Rimkunas,Maria Koehler,Timothy A. Yap +18 more
TL;DR: Changes in ctDNA as early as 3 wks were associated with improved outcomes and may be useful for evaluating drug activity in heterogenous tumors outside of traditional efficacy endpoints.
Journal ArticleDOI
P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
Andrew Eugene Hendifar,Lee S. Rosen,Autumn J. McRee,Andrea Cercek,Atrayee Basu-Mallick,David Spiegel,Sohail F. Tavazoie,E. K. Rowinsky,Maciej Szarek,Fernando Gonsalves,Ina Kurth,Celia Andreu,Robert Busby,Scott L. Spector,Deidra Darst,Narayan Lebaka,Naftali Bechar,Masoud Tavazoie,Ronald Wasserman,Marwan Fakih +19 more
TL;DR: In this paper , RGX-202-01 is a small molecule inhibitor of SLC6A8 that depletes intracellular PCr and ATP, resulting in apoptosis.
Patent
Universal abt compounds and uses thereof
David Spiegel,Matthew Welsch +1 more
TL;DR: In this article, the authors provided compounds comprising universal antibody binding moieties and targeting moieties for treating various diseases including cancer, provided these technologies are useful for treating different diseases, including cancer.